Drug to treat form of leukemia wins approval
Drug approval will boost Pfizer's oncology business
The Food and Drug Administration has approved a pill that treats a rare form of leukemia. The drug's approval is being seen as a major step in increasing drug manufacturer Pfizer, Inc. oncology business.
Bosulif is the second Pfizer cancer drug to get the FDA's approval this year, following its kidney cancer drug Inlyta.
People afflicted with CML have a specific type of genetic mutation called the Philadelphia chromosome. This mutation causes bone marrow to make an enzyme that triggers the abnormal growth of white blood cells.
Bosulif, known generically as bosutinib, works to block the enzyme's signal that causes the white blood cells to grow.
"We are seeing improvements in the treatment of CML based on a better understanding of the molecular basis of the disease," Dr. Richard Pazdur, head of the FDA's cancer drugs center says.
The new drug is intended for people who have CML in connection with the Philadelphia mutation who cannot tolerate other medicines. The drug will also benefit patients whose cancer has stopped responding to older treatments.
The FDA gave Bosulif "orphan status," meaning it treats a condition or disease that affects fewer than 200,000 people in the U.S. This designation will give Pfizer a seven-year period of marketing exclusivity.
Analysts polled by Thomson Reuters say the medicine is expected to reach peak global sales of $341 million in 2016.
Bosulif is the second Pfizer cancer drug to get the FDA's approval this year, following its kidney cancer drug Inlyta. Investors are looking for signs of the company's research productivity, to help replace lost revenue from its cholesterol fighter Lipitor. This comes as welcome news for Pfizer, as it has begun facing generic competition last year.
© 2012, Catholic Online. Distributed by NEWS CONSORTIUM.
- - -
Pope Benedict XVI's Prayer Intentions for January 2013
General Intention: The Faith of Christians. That in this Year of Faith Christians may deepen their knowledge of the mystery of Christ and witness joyfully to the gift of faith in him.
Missionary Intention: Middle Eastern Christians. That the Christian communities of the Middle East, often discriminated against, may receive from the Holy Spirit the strength of fidelity and perseverance.
Keywords: Pfizer, leukemia, FDA, approval, chronic myelogenous leukemia
Rate This Article
Leave a Comment
More Health News
- HIV resurgent among Navajo tribe as deadly cases spike
- UK to give cancer patients genetic analysis just like Angelina Jolie
- Vitamin D found beneficial in treating asthma symptoms
- Study: Depressed women in 40s, 50s suffer more than twice for stroke risk
- Some experts say it's biologically possible to clone a human
- Study: Women live longer than men as their immune systems age more slowly
- Man declared dead for 40 minutes brought back to life with revolutionary machine
- IPad2 poses risks to those with pacemakers, 14-year-old girl discovers
- New SARS-like virus can likely be spread person-to-person
- Fr. Paul Schenck: Finding Living Faith on Catechetical Sunday
- The Movie Yellow: Incest as 'Normal' and Cassavates's Slides Into the World of Woes
- The Chicago School Teachers Strike Reveals the Need For School Choice
- The Sexual Barbarians and the Dissolution of Culture
- The Happy Priest Challenges Us to Ask: Who is Jesus to Me?
- Michael Coren on Canadian Public Schools: Teachers, leave those kids alone
- We Cannot Ignore Our Consciences: Cardinal Dolan On Religious Liberty
- In the Face of Danger, Successor of Peter Travels to Lebanon as a Messenger of Peace
- Reflections on the Dignity and Vocation of Women: Who or What?